Company intelligence / Profile preview

Junshi Runjia

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Junshi Runjia is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company is a joint venture or strategic entity associated with Junshi Biosciences, leveraging deep expertise in cancer biology to target cell cycle regulators and DNA damage repair mechanisms. Its lead programs include inhibitors targeting Aurora kinase A and CDK4/6, aimed at treating various advanced solid tumors. Junshi Runjia operates primarily within the Chinese biopharmaceutical ecosystem, advancing candidates through early-stage clinical trials.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Junshi Biosciences

Beyond the preview

Go deeper on Junshi Runjia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Junshi Runjia.

Explore the full profile